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Previous investigations have shown a significant negative two-way drug interaction between fosamprenavir
(FPV) and lopinavir/ritonavir (LPV/RTV) in both human immunodeficiency virus (HIV)-infected patients and
seronegative volunteers. This randomized, nonblinded, three-way crossover study of HIV-seronegative adult
volunteers investigated dose separation and increased doses of RTV as a means to overcome the interaction
between FPV and LPV/RTV. Eleven HIV-seronegative volunteers were given FPV plus LPV/RTV at 700 mg plus
400/100 mg every 12 hours (q12h) simultaneously for 10 days and then randomized to receive each of three
7-day treatments in one of six possible sequences, as follows: FPV plus LPV/RTV at 700 mg plus 400 mg/100
mg q12h simultaneously, FPV/RTV at 700 mg/100 mg q12h plus LPV/RTV at 400 mg/100 mg q12h, with doses
separated by 4 h, and FPV/RTV at 1,400 mg/200 mg in the morning plus LPV/RTV at 800 mg/200 mg in the
evening. Pharmacokinetic sampling was performed on day 8 of each treatment, and samples were analyzed for
FPV, amprenavir (APV), LPV, and RTV concentrations by high-performance liquid chromatography–tandem
mass spectrometry. Geometric mean ratios (GMR [with 95% confidence intervals]) for the 4- and 12-h dose
separation strategies compared to simultaneous administration were calculated for the areas under the
concentration-time curves from 0 to 24 h. Compared to simultaneous administration, RTV exposures increased
with both 4-h and 12-h dose separation strategies (GMR, 5.30 [3.66 to 7.67] and 4.45 [3.09 to 6.41], respec-
tively). LPV exposures also significantly increased with both 4-h and 12-h dose separation strategies (GMR,
1.76 [1.34 to 2.32] and 1.43 [1.02 to 2.01], respectively). However, both the 4- and 12-h strategies resulted in
greater reductions in APV exposure (0.67 [0.54 to 0.83] and 0.77 [0.59 to 0.99], respectively) compared to
simultaneous administration. Additional investigations are warranted to determine the optimal dosing of FPV
with LPV/RTV.
As larger numbers of antiretroviral-experienced human im-
munodeficiency virus (HIV)-infected patients have fewer op-
tions for therapy, novel combinations of potentially synergistic
and/or complementary antiretrovirals are increasingly being
evaluated. The use of two virologically active protease inhibi-
tors combined with low-dose ritonavir is one such strategy (8,
11, 16, 17, 21, 22, 24, 25, 31). Clinical and pharmacokinetic data
for a combination of the capsule formulation of amprenavir
(APV) (Agenerase; GlaxoSmithKline, Research Triangle Park,
NC) and lopinavir/ritonavir (LPV/RTV) (Kaletra; Abbott Labo-
ratories, Abbott Park, IL) have been published by a number of
investigators (4, 9, 13, 19, 20, 26, 31).
In October 2003, fosamprenavir (FPV), the phosphate ester
prodrug of amprenavir (Lexiva; GlaxoSmithKline), was ap-
proved by the FDA for the treatment of HIV, and as of De-
cember 2004, FPV has replaced Agenerase as the currently
available form of amprenavir. However, recent investigations
have shown that the combination of FPV and LPV/RTV at
standard doses results in significantly lower drug exposures
than FPV/RTV or LPV/RTV alone (13, 29). In Adult AIDS
Clinical Trials Group (ACTG) study A5143, a steady-state
pharmacokinetic (PK) evaluation was performed with HIV-
infected patients receiving either FPV/RTV, LPV/RTV, or
FPV plus LPV/RTV (in combination with tenofovir and one
or two additional nucleoside analogue reverse transcriptase in-
hibitors) (13). Patients receiving this dually boosted combination
of protease inhibitors had a 64% decrease in the APV area under
the concentration-time curve (AUC) and a 50% decrease in the
LPV AUC compared to patients receiving ritonavir-enhanced
protease inhibitors. GlaxoSmithKline investigated alternative
dosing of FPV/RTV with LPV/RTV in seronegative volunteers
(29). The following two regimens resulted in LPV concentrations
similar to or slightly higher than those obtained with LPV/RTV at
400/100 mg every 12 h: (i) FPV at 1,400 mg plus LPV/RTV at
533/133 mg twice a day (BID) and (ii) FPV at 700 mg plus
LPV/RTV at 400/100 mg plus RTV at 100 mg BID. However,
neither of these regimens resulted in APV concentrations similar
to those obtained with FPV/RTV at 700/100 mg every 12 h. The
regimen of 1,400 mg FPV with 533/133 mg LPV/RTV resulted in
APV exposures of 58 to 87% those obtained with FPV/RTV
alone, but 31% (11 of 36) of subjects discontinued this regimen
due to adverse effects, such as gastrointestinal disturbances, head-
aches, oral/perioral numbness, pruritis, and rash.
The mechanism of this interaction is unclear. Since increas-
ing doses of FPV and LPV/RTV resulted in a less tolerable
regimen and did not fully overcome the drug interaction, ad-
ditional strategies for coadministration need to be explored.
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Alternative hypotheses for the interaction include the involve-
ment of a physical incompatibility or an acute local interaction
involving drug-metabolizing enzymes and/or transporters.
Therefore, it was anticipated that separating the administra-
tion of FPV and LPV/RTV would result in higher drug expo-
sures than those after simultaneous administration of all three
antiretrovirals.
MATERIALS AND METHODS
A prospective, randomized, nonblinded, three-way crossover study of healthy
adult HIV-negative volunteers was conducted to compare the PK parameters of
FPV, APV, LPV, and RTV when FPV was administered simultaneously with, 4
hours prior to, or 12 hours prior to LPV/RTV.
Healthy volunteers were screened and enrolled if they were 18 to 45 years old,
tested HIV seronegative by an enzyme-linked immunosorbent assay, and
weighed 50 kg. Subjects were excluded if they had a previous hypersensitivity
to APV, LPV, or RTV; were 20% over ideal body weight; were pregnant (by
positive serum human chorionic gonadotropin); were taking concomitant pre-
scription, nonprescription, herbal, or illicit drugs; were unable to abstain from
alcohol or grapefruit products while enrolled; or had any of the following labo-
ratory abnormalities: hematocrit of 30 g/dl; total cholesterol level of 240
mg/dl; triglyceride level of 400 mg/dl; fasting glucose level of 120 mg/dl;
alanine aminotransferase, aspartate aminotransferase, gamma glutamyl trans-
ferase, or bilirubin level of more than twice the upper limit of normal; or albumin
level of 3.5 g/dl. The human experimentation guidelines of the U.S. Depart-
ment of Health and Human Services and those of the University of North
Carolina at Chapel Hill, as well as Health Insurance Portability and Account-
ability Act regulations, were followed in the conduct of this clinical research
study.
Subjects meeting the above criteria were initially given FPV and LPV/RTV
simultaneously for 10 days due to the potential drug-metabolizing enzyme-in-
ducing capacities of APV (6, 27) and LPV/RTV (30). However, it was acknowl-
edged that the lower drug exposures with this combination could potentially
impact the maximal influence on drug-metabolizing enzyme activity. If the dose
separation strategies successfully increased drug exposure, more time would be
needed to achieve steady-state conditions. Therefore, after this initial phase,
each subject in this prospective, nonblinded, three-treatment, three-period, six-
sequence crossover study was assigned by a randomization schedule to one of the
six treatment sequences described below (ABC, ACB, BAC, BCA, CAB, and
CBA), generated via SAS System software (version 8.2), as summarized in Table 1.
The study design and randomization procedure specified a balanced allocation of
12 subjects to the six sequences, i.e., 2 subjects per sequence. On day 11, subjects
began the assigned sequences with an initial treatment of either (i) FPV at 700
mg BID plus LPV/RTV at 400/100 mg BID (given simultaneously) (treatment
A), (ii) FPV/RTV at 700/100 mg BID plus LPV/RTV at 400/100 mg BID (given
4 h apart) (treatment B), or (iii) FPV/RTV at 1,400/200 mg once a day (QD) plus
LPV/RTV at 800/200 mg QD (given 12 h apart) (treatment C). Each treatment
was given for 7 days. On day 8, subjects were admitted to the General Clinical
Research Center at UNC for intensive PK sampling. After the first PK visit,
subjects crossed over to each of the other two treatments. Intensive PK sampling
was performed at the end of each 7-day treatment.
Fosamprenavir (700-mg tablets [investigational during the study period]
[GlaxoSmithKline, Research Triangle Park, NC]), lopinavir/ritonavir (Kaletra;
133/33-mg capsules [Abbott Laboratories, Abbott Park, IL]), and ritonavir
(Norvir; 100-mg capsules [Abbott Laboratories, Abbott Park, IL]) were supplied
by GlaxoSmithKline and used throughout the study.
The evening prior to PK sampling, study subjects were admitted to the Verne S.
Caviness General Clinical Research Center at the University of North Carolina
Hospitals. Evening doses of FPV, LPV/RTV, and additional RTV (if applicable)
were observed and recorded. Adherence was assessed by pill counts and medi-
cation administration records. After an overnight fast, the morning dose of each
medication was administered with a standardized meal, and the time was re-
corded. For the visits in which the doses were separated, FPV/RTV and LPV/
RTV were given with standardized meals. The total daily caloric intake per visit
was standardized to 2,000 to 2,500 cal, made up of 55% carbohydrates, 30% fat,
and 15% protein.
Each PK sampling schedule varied in length depending on the treatment being
investigated. For treatment A, blood samples were obtained at 0 h (predose) and
0.5, 1, 2, 4, 6, 8, and 12 h after the doses of FPV plus LPV/RTV. For treatment
B, the blood sampling scheme was designed to characterize the full 12-hour PK
profiles of both FPV/RTV and LPV/RTV (given 4 h after FPV/RTV), using the
following times: 0 h (pre-FPV/RTV dose) and 0.5, 1, 2, 4 (pre-LPV/RTV dose),
4.5, 5, 6, 8, 10, 12, and 16 h after the FPV/RTV dose. Likewise, for treatment C,
the blood sampling scheme was designed to characterize the full 24-h PK profiles
of FPV/RTV and LPV/RTV, using the following times: 0 h (pre-FPV/RTV dose)
and 0.5, 1, 2, 4, 6, 8, 12 (pre-LPV/RTV), 12.5, 13, 14, 16, 18, 20, 24, 30, and 36 h
after the FPV/RTV dose. Whole blood was collected in sodium citrate (for APV
and FPV)- or sodium heparin (for LPV and RTV)-containing Vacutainer tubes
(Becton Dickinson). Blood tubes were inverted to ensure mixing of the antico-
agulant and whole blood and were centrifuged at 2,000 rpm at 4°C within 30 min
of collection. Plasma was aliquoted and stored at 70°C until analysis.
APV and FPV concentrations were measured by Advion Biosciences (Ithaca,
NY). Briefly, 50 l of blood plasma was subjected to solid-phase extraction
followed by high-performance liquid chromatography–tandem mass spectrome-
try detection with a Turbo ion-spray interface and multiple reaction monitoring
in the positive-ion mode. This method has lower limits of quantification of 10
ng/ml for amprenavir and 5 ng/ml for FPV. Linearity was demonstrated up to the
higher limits of quantification of 10,000 ng/ml for amprenavir and 1,000 ng/ml for
FPV. All samples were analyzed on the same day, with an intraday variability of
12% for FPV and 6% for APV.
LPV and RTV concentrations were measured by Covance Laboratories, Inc.
(Madison, WI). Briefly, 100 l of blood plasma was processed by solvent extrac-
tion. Extracts were analyzed by high-performance liquid chromatography–tan-
dem mass spectrometry using atmospheric-pressure chemical ionization. This
method has lower limits of quantification of 10 ng/ml for RTV and 20 ng/ml for
LPV. Linearity was demonstrated up to the higher limits of quantification of
10,000 ng/ml for RTV and 20,000 ng/ml for LPV. All samples were analyzed on
the same day, with an intraday variability of 14% for LPV and 13% for RTV.
Noncompartmental pharmacokinetic analysis was performed using WinNonLin
Pro (V4.0.1; Pharsight, Mountain View, CA) software. The AUC over the dosing
interval (AUC0-) was calculated using the linear-log trapezoidal rule. Additional
PK parameters analyzed included the maximum concentration (Cmax), time to
maximum concentration (Tmax), and concentration at the end of the dosing
interval (C). For treatments A and B,  was defined as 12 h, and for treatment
C,  was defined as 24 h.
Adverse events were assessed by a questionnaire administered at each study
visit. In addition, a clinician performed physical exams on all subjects at screen-
ing and at each study visit. Laboratory parameters obtained at baseline were
evaluated at each study visit. The ACTG toxicity grading scale was used for
toxicity documentation (2). Subjects experiencing grade 3 or 4 toxicity were
reported to the UNC Institutional Review Board and subsequently withdrawn
from the study. In addition, any subjects with the following elevations were
withdrawn from the study: fasting cholesterol level of 280 mg/dl, triglyceride
level of 500 mg/dl, blood glucose level of 120 mg/dl, and aspartate amino-
transferase or alanine aminotransferase level of more than twice the upper limit
of normal at any time during the study. Blood sampling was not conducted for
any subject with a hematocrit of 30%.
The primary outcome measures for this study were the amprenavir AUC0-
and C. The sample size was conservatively calculated using APV C values,
which are more variable than AUC0- values (coefficients of variation, 43 and
29%, respectively) (4). Using this parameter, a sample size of 11 at a significance
level of 0.05 was calculated to have 85% power to detect at least a 30%
difference in means across the three levels of repeated measures. Secondary
TABLE 1. Study designa
Group Samplesize (n)
Treatment during period:
1 (days 11–17) 2 (days 18–24) 3 (days 24–30)
1 2 A B C
2 2 B C A
3 2 C A B
4 1 A C B
5 2 B A C
6 2 C B A
a Lead-in phase, FPV at 700 mg BID plus LPV/RTV at 400/100 mg BID
(given simultaneously) for 10 days; treatment A, FPV at 700 mg BID plus
LPV/RTV at 400/100 mg BID (given simultaneously) for 7 days; treatment B,
FPV/RTV at 700/100 mg BID plus LPV/RTV at 400/100 mg BID (given 4 hours
prior to FPV/RTV) for 7 days; treatment C, FPV/RTV at 1,400/200 mg QD plus
LPV/RTV at 800/200 mg QD (given 12 hours prior to FPV/RTV) for 7 days.
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outcome measures were the lopinavir and ritonavir AUC0- and C. Summary
statistics were generated for the following parameters for all drugs across all
treatments: C, AUC0-, Cmax, and Tmax. Geometric means (GMs), geometric
mean ratios (GMRs), and their respective 95% confidence intervals (95% CI) for
AUC0- and C values were calculated using SAS 8.2 software (SAS, Cary, NC).
When twice-daily dosing was used, the AUC0-24 was calculated by multiplying by
2. The primary analysis of amprenavir AUC0- and C values used a mixed model
with a compound symmetry covariance structure, with adjustment for period
effects. Demographic data are reported as means  standard deviations (SD),
while pharmacokinetic data are presented as geometric means with 95% CI.
RESULTS
A total of 15 healthy volunteers were enrolled in the study,
and 11 completed all periods of the study, from January to
June 2003. Four subjects withdrew prematurely due to adverse
events, with three withdrawing during the first 10 days of the
lead-in phase due to grade 2 rashes (considered drug related)
and one withdrawing after 25 days due to leukocytosis and
folliculitis (not considered drug related). Of the 11 subjects
who completed the study, 10 were male, 9 were Caucasian, and
2 were African-American. These subjects had a mean (SD) age
of 23 (5.5) years and a mean (SD) weight of 81 (12.87) kg.
Table 2 contains pharmacokinetic data for APV, LPV, and
RTV for each treatment, along with treatment comparisons.
Figure 1 shows graphical representations of the geometric
mean concentration-time data for APV, LPV, and RTV across
all three treatments.
Compared to those after simultaneous drug administration,
the APV C and AUC0- when FPV/RTV was given 4 hours
prior to LPV/RTV declined by 49% (95% CI, 19 to 68%; P 
0.02) and 33% (95% CI, 17 to 46%; P  0.02), respectively,
while the LPV C and AUC0- increased by 171% (95% CI, 45
to 405%; P  0.02) and 76% (95% CI, 34 to 132%; P 
0.02), respectively.
Compared to those after simultaneous drug administration,
the APV C and AUC0- when FPV/RTV was given 12 h prior
to LPV/RTV declined by 72% (95% CI, 59 to 81%; P  0.02)
and 23% (95% CI, 1 to 41%; P  0.02), respectively, while the
LPV C and AUC0- increased by 69% (95% CI, 3 to 195%;
P  0.10) and 43% (95% CI, 2 to 101%; P  0.02), respec-
tively.
With dose separation, the total daily dose of RTV increased
from 200 mg to 400 mg. Compared to those after simultaneous
administration, the RTV C and AUC0- increased 826% (447
to 1,468%) and 430% (266 to 667%), respectively, with a
4-hour separation and 394% (144 to 900%) and 345% (209 to
541%), respectively, with a 12-hour separation.
To further understand the mechanism of the FPV-LPV/
RTV interaction, plasma concentrations of FPV were quanti-
fied. Detectable FPV concentrations were found in only 5 of
407 samples, representing 4 of 11 subjects. These concentra-
tions ranged from 6.12 to 8.43 ng/ml. There was no pattern in
the detectable concentrations with respect to treatment phase
or time within the dosing interval.
Adverse events, such as rash, gastrointestinal upset (diar-
rhea, loose stools, or nausea), and perioral paresthesias, were
documented. Three of 15 subjects discontinued the study after
6, 7, and 9 days of simultaneous administration due to drug-
related, grade 2 maculopapular rashes. In all cases, the rash
resolved within 14 days after treatment with antihistamines.
One patient withdrew during the last period of the study due to
non-drug-related leukocytosis and folliculitis. These were suc-
cessfully treated with a short course of minocycline and topical
clindamycin. All subjects experienced loose stools for an aver-
age of 23.8 days, which resolved with (n  4) or without (n 
7) antidiarrheal therapy (loperamide or atropine/diphenoxy-
late). Four subjects had grade 1 or 2 diarrhea for an average of
13 days, with three of the four having diarrhea only during
treatments B and C, where an additional 200 mg of RTV was
given daily. However, no subjects withdrew from the study due
to gastrointestinal tract-related side effects. No subjects expe-
rienced diarrhea during their pharmacokinetic visits. Four sub-
jects had taste perversion for 6 to 30 days, and two subjects had
perioral paresthesia for 30 days.
Adherence to the study medication was acceptable through-
TABLE 2. Steady-state PK parameters for APV, LPV, and RTV given in various dosing strategiesa
Study drug and APV
PK parameter
GM (95% CI) GMR (95% CI)
A Bb Cb B/A C/A C/B
APV
Cmax (g/ml) 1.88 (1.47, 2.40) 1.24 (1.06, 1.44) 2.94 (1.98, 4.37) 0.66 (0.54, 0.80) 1.56 (1.02, 2.41) 2.37 (1.57, 3.58)
AUC (g · h/ml) 10.21 (7.99, 13.04) 6.82 (5.36, 8.69) 0.67 (0.54, 0.83)
AUC24 (g · h/ml) 20.42 (15.98, 26.08) 13.64* (10.72, 17.38) 15.67* (11.39, 21.55) 0.77 (0.59, 0.99) 1.15 (0.88, 1.50)
C (g/ml) 0.52 (0.37, 0.75) 0.27* (0.17, 0.41) 0.15* (0.08, 0.26) 0.51 (0.32, 0.81) 0.28 (0.19, 0.41) 0.55 (0.33, 0.92)
LPV
Cmax (g/ml) 8.10 (6.03, 10.87) 12.98* (11.07, 15.21) 12.42* (9.09, 16.96) 1.60 (1.31, 1.95) 1.53 (1.20, 1.95) 0.96 (0.75, 1.22)
AUC (g · h/ml) 69.50 (46.26, 104.41) 122.48 (103.02, 145.63) 1.76 (1.34, 2.32)
AUC24 (g · h/ml) 139.00 (92.52, 208.82) 244.96* (206.04, 291.26) 199.18* (127.36, 311.50) 1.43 (1.02, 2.01) 0.81 (0.55, 1.20)
C (g/ml) 2.98 (1.51, 5.91) 8.08* (6.79, 9.60) 5.03 (2.10, 12.04) 2.71 (1.45, 5.05) 1.69 (0.97, 2.95) 0.62 (0.25, 1.53)
RTV
Cmax (g/ml) 0.59 (0.40, 0.87) 2.83* (1.88, 4.26) 3.30* (2.25, 4.85) 4.84 (2.98, 7.86) 5.65 (4.06, 7.86) 1.17 (0.72, 1.90)
AUC (g · h/ml) 3.87 (2.73, 5.49) 20.50 (14.09, 29.84) 5.30 (3.66, 7.37)
AUC24 (g · h/ml) 7.74 (5.46, 10.98) 41.00* (28.18, 58.68) 34.43* (21.73, 54.55) 4.45 (3.09, 6.41) 0.84 (0.51, 1.37)
C (g/ml) 0.15 (0.10, 0.22) 1.36* (0.80, 2.32) 0.72* (0.33, 1.59) 9.26 (5.47, 15.68) 4.94 (2.44, 10.00) 0.53 (0.25, 1.14)
a Treatment A (n  11), FPV at 700 mg BID plus LPV/RTV at 400/100 mg BID (given simultaneously) for 7 days; treatment B (n  11), FPV/RTV at 700/100 mg
BID plus LPV/RTV at 400/100 mg BID (given 4 hours prior to FPV/RTV) for 7 days; treatment C (n  11), FPV/RTV at 1,400/200 mg QD plus LPV/RTV at 800/200
mg QD (given 12 hours prior to FPV/RTV) for 7 days. The AUC24 values for treatments A and B are based on 2	 the observed AUC12. *, P  0.02 compared to
treatment A.
b RTV daily dose was increased by 200 mg.
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out the investigation. By diary and pill counts, five subjects
were 100% adherent and six subjects were 89 to 99% adherent
to their study medication.
DISCUSSION
Drug interactions between protease inhibitors can be unpre-
dictable. This is due in part to the complex interaction between
cytochrome P450 (CYP) enzyme activity, cellular membrane
transporter (e.g., p-glycoprotein) activity, and protein binding
(18). Despite these complex interactions, dually boosted pro-
tease inhibitor regimens are commonly used therapies for
HIV-infected patients with limited treatment options, al-
though efficacy data are limited (6, 9, 19, 24).
The pharmacokinetics of the combination of APV (the
Agenerase formulation) and LPV/RTV have been investigated
in a number of publications (4, 19, 20, 26). Compared to the
data for APV at 600 mg BID given with RTV at 100 mg BID,
these data suggest that APV concentrations are decreased
when it is coadministered with LPV/RTV at 400/100 mg BID.
However, one study demonstrated comparable APV concen-
trations to those of historic controls (APV at 600 mg and RTV
at 100 mg BID) when APV at 750 mg BID was coadministered
with LPV/RTV (4).
FIG. 1. Curves of geometric mean concentration versus time. Treatment A (n  11), FPV at 700 mg BID plus LPV/RTV at 400/100 mg BID
(given simultaneously) for 7 days; treatment B (n  11), FPV/RTV at 700/100 mg BID plus LPV/RTV at 400/100 mg BID (given 4 h prior to
FPV/RTV) for 7 days; treatment C (n  11), FPV/RTV at 1,400/200 mg QD plus LPV/RTV at 800/200 mg QD (given 12 h prior to FPV/RTV)
for 7 days. (A) Amprenavir curve; (B) lopinavir curve; (C) ritonavir curve.
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Data from GlaxoSmithKline evaluating the interaction be-
tween fosamprenavir and LPV/RTV also demonstrated a de-
cline in APV concentrations when it was given with LPV/RTV.
Administering an extra 100 mg BID of RTV along with the
standard doses of FPV and LPV/RTV resulted in lower FPV
exposure than treatment with FPV/RTV alone (65% decrease
in APV C and 63% decrease in APV AUC0-). Doubling the
FPV dose to 1,400 mg BID and increasing the doses of LPV/
RTV to 533/133 mg BID also resulted in lower FPV exposure
than that with FPV/RTV alone (42% decrease in APV C and
26% decrease in APV AUC0-). However, both of these FPV/
LPV/RTV combination regimens were poorly tolerated in this
healthy volunteer population, with 31 to 33% of subjects dis-
continuing treatment due to adverse events, which were mostly
gastrointestinal in nature.
Since the APV interaction cannot be overcome by increasing
doses of FPV or RTV, it was hypothesized that a physical
incompatibility between FPV and LPV/RTV or an acute local
interaction involving drug-metabolizing enzymes and/or trans-
porters may affect the absorption phase of the pharmacoki-
netic profile. A strategy of physical dose separation was pur-
sued. While the 12-h dose separation strategy was studied for
its practical application to patient therapy, the 4-h dosage
separation strategy was pursued to examine whether a short
physical separation could overcome any potential absorption
interaction. Previously, this type of dosing strategy has been
shown to overcome the effects of antacids on fluoroquinolone
antibiotics, itraconazole, and protease inhibitors (3, 14, 23).
Additionally, with the 4-h separation strategy, RTV was given
simultaneously with FPV instead of relying on the RTV com-
ponent of LPV/RTV to boost APV concentrations. This deci-
sion was based on data from ACTG study 378, in which opti-
mal concentrations of saquinavir (SQV) were achieved when
RTV was given simultaneously with SQV, in contrast to when
RTV was given 4 h before or after SQV (28).
None of our dose separation strategies were able to avoid
the effects of LPV/RTV on the APV concentration. In fact,
when FPV and LPV/RTV were separated by 4 and 12 h,
concentrations of APV were further decreased (the AUC0-
GMR [95% CI] for the 4-h strategy was 0.67 [0.54 to 0.83], and
that for the 12-h strategy was 0.77 [0.59 to 0.99]), despite the
fact that patients received twice the total daily dose of RTV.
Since this investigation did not include subjects receiving FPV/
RTV and LPV/RTV alone, we can only compare exposures in
this study to historic data from healthy volunteers (29). APV
concentrations in all treatment arms were substantially lower
than historic data (geometric mean APV AUC0-, C, and Cmax
for FPV/RTV at 700/100 mg BID, 36.5 h · g/ml, 2.35 g/ml,
and 5.72 g/ml, respectively) (29). LPV concentrations were
lower than historic controls when given simultaneously with
FPV (geometric mean LPV AUC0-, C, and Cmax for LPV/
RTV at 400/100 mg BID, 92.6 h · g/ml, 6.05 g/ml, and 11.3
g/ml, respectively). However, both the 4-h and 12-h strategies
returned LPV exposure to values seen in HIV-infected pa-
tients and healthy volunteers using both twice-daily and once-
daily regimens (4, 13, 29). We attribute this increase in LPV
exposure to an increase in RTV dosing, similar to what was
seen with other dosing strategies in healthy volunteers (29).
In this investigation, the exposure of APV when FPV and
LPV/RTV were given in standard doses was lower than that
reported for HIV-infected subjects (13). Therefore, it is pos-
sible that our results might differ from data from an HIV-
infected patient population. However, reports of disparate PK
data between HIV-infected patients and healthy volunteers are
rare. Due to the extreme nature of this interaction and the
higher drug exposure needed in an antiretroviral treatment-
experienced patient population, it is unlikely that a dose sep-
aration strategy would be effective in these patients.
Additional considerations of a mechanism for this interac-
tion include changes in alkaline phosphatase activity and/or
protein binding interactions. Fosamprenavir is converted to
APV at and/or in the intestinal epithelium by alkaline phos-
phatase (7). Although LPV has not been shown to affect alka-
line phosphatase activity in vitro (GlaxoSmithKline, personal
communication), other excipients in the Kaletra formulation
have not been tested. In this investigation, detection of FPV in
the plasma was sporadic, and no differences were seen between
the dosing groups.
Protein binding displacement interactions between these
protease inhibitors could result in lower total drug concentra-
tions of APV, which would not be overcome with increased
doses or dose separation. APV and LPV are 90% and 98%
protein bound, respectively, and primarily bind to alpha-1-acid
glycoprotein and albumin (1, 7). If LPV displaced APV from
these proteins, a decrease in the total APV concentration (with
no change in unbound/free drug APV concentrations) would
be expected (5). This interaction would have no clinical con-
sequences, since the unbound concentration represents the
amount of drug available to exert antiviral activity. However,
Taburet et al. noted a decline in both total and free APV
concentrations in nine individuals given 400/100 mg LPV/RTV
with 600 mg APV plus either 100 or 200 mg of RTV (as the
Agenerase formulation). The decline in total drug concentra-
tion suggests a protein binding displacement of APV. The
decline in unbound concentration suggests that additional
mechanisms are likely to be involved, such as the induction of
CYPs or other transporters (26).
Finally, it was previously observed that combining lopinavir
with ritonavir in vitro leads to a 10-fold decrease in the CYP3A
inhibitory potency of ritonavir (15). If there were a similar
magnitude of discrepancy in ritonavir inhibition in patients,
even doubling the dose of ritonavir would not be sufficient to
achieve adequate inhibition of APV metabolism and increase
drug concentrations to baseline.
The results of this study suggest that the interaction between
FPV and LPV/RTV is neither a physicochemical incompati-
bility nor an acute effect on drug-metabolizing enzymes or
transporters that can be overcome by separating or increasing
drug doses. Further investigation into the mechanisms of this
interaction are warranted, including looking into possible
chronic induction effects on drug-metabolizing enzymes and/or
transporters (10, 12). Alternate strategies need to be devised to
allow effective coadministration of these antiretroviral agents.
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